Bausch + Lomb Corporation announced its second-quarter 2025 financial results, reporting a revenue of $1.278 billion, reflecting a 5% increase as reported and a 3% rise on a constant currency basis compared to the same quarter in 2024. The company recorded a GAAP net loss attributable to Bausch + Lomb Corporation of $62 million. Adjusted EBITDA, excluding Acquired IPR&D (non-GAAP), was $192 million for the quarter. In terms of earnings per share, the adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP) was $0.07 for the second quarter of 2025, compared to $0.13 in the same period of 2024. The company has raised its full-year 2025 guidance to reflect solid business performance and the impact of foreign exchange, with full-year revenue foreign exchange tailwinds anticipated to be nominal. Operational highlights include the resumption of full production of all enVista® platform intraocular lenses following their return to the market. The company also reported reaching approximately $1 billion in trailing 12-month revenue across its dry eye portfolio and achieving broad-based growth in Vision Care, led by key contact lens franchises. Bausch + Lomb successfully executed a refinancing transaction, thereby extending its maturity profile.